23S Ribosomal RNA

23S ribosomal RNA (23S rRNA) is the large catalytic polyribonucleotide molecule that forms the structural scaffold and enzymatic active site of the 50S large ribosomal subunit in Bacteria and Archaea (sedimenting at 23 Svedberg units with a molecular mass of ~0.95 MDa). In the reference bacterium Escherichia coli, the mature 23S rRNA molecule consists of 2,904 nucleotides co-transcribed with 16S ribosomal RNA and 5S rRNA across seven chromosomal rrn operons (rrlA–rrlH). Folding into 101 base-paired helices partitioned across six secondary-structure domains (Domains I–VI) that radiate from a central core, 23S rRNA complexes with 5S rRNA and 33 large-subunit ribosomal proteins (uL1–bL36) to assemble the 50S subunit.

Crucially, atomic-resolution crystal structures of the 50S subunit solved by Thomas Steitz, Peter Moore, Ada Yonath, and colleagues established that the ribosome is a ribozyme: Domain V of 23S rRNA constructs the entire peptidyl transferase center (PTC) with no ribosomal protein side chains within 18 Å of the site of peptide bond synthesis. Because Domain V and the adjacent nascent peptide exit tunnel (NPET) also house the primary binding pockets for macrolide, lincosamide, streptogramin B (MLS_B), chloramphenicol, and oxazolidinone antibiotics, 23S rRNA is a central locus of clinical antimicrobial resistance, governed by enzymatic A2058 methylation and strong non-additive epistasis (Potts coupling |*J*_2058,2611| = 2.642).

Domains I–VI and Inter-Subunit Bridge Networks

Unlike the modular domains of 16S ribosomal RNA, which fold into semi-independent lobes of the 30S subunit, the six secondary-structure domains (Domains I–VI) of 23S rRNA interdigitate through long-range coaxial helix stacking, A-minor motifs, and magnesium-chelated phosphate bridges to form a monolithic hemispherical block:

• Domains I, II, and III: Form the solvent-exposed back and lower hemisphere of the 50S subunit and line the interior walls of the nascent peptide exit tunnel (~100 Å long and 10–20 Å wide). Domain II also contains the GTPase-associated center (GAC, Helices 42–44) and the L11 stalk, which stimulate GTP hydrolysis by translational factors EF-Tu, EF-G, and IF2.
• Domain IV: Forms the flat 50S interface surface that contacts the 30S subunit via conserved RNA–RNA inter-subunit bridges (notably Bridge B2a, where Helix 69 of 23S rRNA inserts directly into the decoding center of 16S Helix 44).
• Domain V (Helices 73–93): Forms the central protuberance (together with 5S rRNA), the L1 stalk (which facilitates E-site deacylated tRNA release), and the central peptidyl transferase center ring.
• Domain VI (Helix 95): Contains the universally conserved α-sarcin/ricin loop (SRL), an S-turn motif essential for anchoring elongation factors during translation.

Ribozyme Catalysis at A2451 and the Proton-Shuttle Mechanism

During the elongation cycle of protein synthesis, the peptidyl transferase center inside Domain V positions the 3′-CCA terminus of aminoacyl-tRNA in the A-site (via base-pairing of G2553 in the A-loop, Helix 92, with tRNA C75) adjacent to the 3′-CCA terminus of peptidyl-tRNA in the P-site (via base-pairing of G2251 and G2252 in the P-loop, Helix 80, with tRNA C75 and C74).

The inner shell of the PTC is encircled by five universally conserved 23S rRNA nucleotides: A2451, U2506, U2585, C2452, and A2602 (E. coli numbering). Peptide bond synthesis proceeds via nucleophilic attack of the α-amino group (–NH₂) of the A-site aminoacyl-tRNA on the ester carbonyl carbon of the P-site peptidyl-tRNA, accelerating the uncatalyzed reaction rate by ~10⁷-fold:

1. Entropic Positioning and Induced Fit: Binding of the A-site CCA end triggers a conformational rearrangement of U2585 and U2506, exposing the P-site ester carbonyl in the precise inline attack geometry (decreasing the activation entropy Δ*S*^‡).
2. The A2451 / P-Site A76 2′-OH Proton Shuttle: The 2′-hydroxyl group of A2451 hydrogen-bonds directly to the 2′-OH group of the P-site tRNA terminal adenosine (A76). Acting as a concerted eight-membered-ring proton shuttle, the A76 2′-OH abstracts a proton from the attacking α-NH₂ nucleophile while simultaneously donating a proton to the leaving 3′-oxygen of the deacylated P-site tRNA, stabilizing the tetrahedral oxyanion intermediate alongside a coordinated water molecule.

MLS_B Macrolides in the Exit Tunnel vs. Oxazolidinones in the PTC

Because prokaryotic 23S rRNA diverges from eukaryotic cytoplasmic 28S ribosomal RNA at key second-shell nucleotides around the PTC and upper exit tunnel, over half of clinically deployed ribosome-targeting antibacterial classes bind directly to Domain V of 23S rRNA:

Macrolides (such as erythromycin and azithromycin) bind ~10 Å below the PTC inside the upper nascent peptide exit tunnel, where the desosamine sugar of the macrolide lactone ring forms a critical hydrogen bond with the N1/N6 atoms of A2058 and A2059, supported by the base pair G2057:C2611 closing the tunnel wall. Rather than blocking every peptide bond, macrolides act as context-specific plugs that arrest translation when specific nascent peptide sequences (such as +X+ positively charged motifs) encounter the drug-bound tunnel.

In contrast, synthetic oxazolidinones (such as linezolid) bind directly inside the A-site pocket of the PTC, stacking against U2504 and C2452 to prevent the aminoacyl moiety of incoming A-site tRNAs from entering the catalytic site.

Erm Methyltransferases and Multi-Operon Copy-Number Dosage

Bacteria evolve clinical resistance to 23S-targeting antibiotics through two distinct genetic pathways:

1. Enzymatic rRNA Modification (erm and cfr genes): Horizontally transferred Erm methyltransferases (ermA, ermB, ermC) catalyze S-adenosylmethionine-dependent N6-mono- or dimethylation of A2058 (m⁶₂A2058). The bulky methyl groups sterically clash with the desosamine sugar of macrolides, lincosamides, and streptogramin B, conferring the MLS_B cross-resistance phenotype across all newly assembled 50S subunits simultaneously. Similarly, the radical-SAM methyltransferase Cfr methylates the C8 carbon of A2503 (m⁸A2503), conferring resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A (PhLOPS_A phenotype).
2. Chromosomal Point Mutations (A2058G and G2576U) and Gene Dosage: Because bacteria with low rrn operon copy numbers (such as Mycobacterium tuberculosis with 1 copy, or Helicobacter pylori with 2 copies) express mutant ribosomes immediately upon acquiring a single point mutation, chromosomal A2058G or A2059G mutations are the dominant cause of macrolide resistance in these pathogens. Conversely, in multi-copy pathogens such as Staphylococcus aureus (5–6 rrn operons) or Enterococcus faecium (6 operons), linezolid resistance via the second-shell mutation G2576U exhibits a strict gene-dosage relationship: minimal inhibitory concentrations (MICs) rise above the clinical breakpoint (>4 μg/mL) only after homologous recombination converts at least 2 to 4 of the 6 rrl copies to the mutant 2576U allele.

Potts Co-Evolutionary Epistasis in Domain V

Why can bacteria not freely mutate first-shell PTC nucleotides (such as A2451, U2504, or A2058) without incurring lethal or debilitating fitness penalties? Direct Coupling Analysis (DCA) and Potts statistical physics models fit across thousands of bacterial 23S rRNA Domain V alignments reveal an intricate network of pairwise co-evolutionary couplings (J_ij):

• The 2058–2611 Tunnel Gate (|J_2058,2611| = 2.642): Position A2058** is strongly coupled to the closing base pair G2057:C2611 across the exit tunnel constriction. Introducing an isolated A2058G or C2611U mutation without compensatory adjustments in the 2057:2611 pair or ribosomal proteins uL4 and uL22 destabilizes the tunnel wall by an epistatic energy penalty of Δ*E* = +14.7 kcal/mol in Potts Hamiltonian units, reducing 50S assembly efficiency and translation elongation rates by 20%–35% in antibiotic-free media.
• The U2504:G2576 Second-Shell Stack (|J_2504,2576| = 2.18): Because first-shell U2504** directly borders the PTC active site, direct mutations at 2504 severely impair peptidyl transfer. Clinical linezolid-resistant strains instead select G2576U in the adjacent second shell, which perturbs the stacking geometry of U2504 just enough to displace linezolid while preserving residual PTC catalysis, often followed by compensatory mutations in ribosomal protein uL3 (rplC) that restore fitness.

Consequently, clinical genomic diagnostics that call isolated sub-clonal SNVs in 23S Domain V without evaluating multi-operon allele fraction and Potts compensatory coupling context fail to distinguish transient high-cost variants from stable epidemic resistance clones.

How did structural biologists prove that the ribosome is an RNA enzyme (ribozyme) rather than a protein enzyme?

In 2000, Thomas Steitz, Peter Moore, and colleagues solved the 2.4 Å X-ray crystal structure of the Haloarcula marismortui 50S ribosomal subunit complexed with a transition-state analog (CCdA-phosphate-puromycin) bound in the peptidyl transferase center. The electron density map demonstrated that the entire catalytic pocket is constructed from conserved nucleotides of Domain V of 23S rRNA (including A2451, U2506, and U2585), with the closest polypeptide atom (belonging to ribosomal protein uL3) located more than 18 Å away from the nascent peptide bond—far too distant to participate in chemical catalysis.

Why do Helicobacter pylori and Mycobacterium develop macrolide resistance via 23S point mutations, whereas Staphylococcus and Streptococcus usually acquire erm genes?

Because macrolide susceptibility is dominant or co-dominant when wild-type and mutant 50S subunits coexist in the same cell, a single chromosomal A2058G mutation confers immediate high-level clarithromycin resistance in Helicobacter pylori (2 rrn operons), Mycobacterium tuberculosis (1 rrn operon), and Mycoplasma pneumoniae (1 rrn operon). In contrast, Staphylococcus aureus (5–6 operons) and Streptococcus pneumoniae (4 operons) would have to mutate multiple operons sequentially via gene conversion; instead, they much more rapidly acquire a plasmid- or transposon-borne erm methyltransferase gene whose enzyme methylates A2058 across 100% of cellular 23S rRNA molecules.

Why do clinical linezolid-resistant bacteria mutate G2576U rather than mutating the nucleotides that directly touch linezolid?

Linezolid binds inside the first shell of the peptidyl transferase center directly against universally conserved nucleotides A2451, C2452, and U2504. Because these first-shell nucleotides are required to orient the A-site aminoacyl-tRNA during every peptide bond reaction, direct mutations at 2451 or 2452 are lethal. By mutating the second-shell nucleotide G2576U (which base-pairs/stacks behind U2504), bacteria indirectly shift the position of U2504 by ~1.2 Å—reducing linezolid binding affinity 8- to 16-fold while retaining viable protein synthesis rates.

1. Ban, N., Nissen, P., Hansen, J., Moore, P. B., & Steitz, T. A. (2000). "The complete atomic structure of the large ribosomal subunit at 2.4 Å resolution." Science, 289(5481), 905–920. https://doi.org/10.1126/science.289.5481.905
2. Nissen, P., Hansen, J., Ban, N., Moore, P. B., & Steitz, T. A. (2000). "The structural basis of ribosome activity in peptide bond synthesis." Science, 289(5481), 920–930. https://doi.org/10.1126/science.289.5481.920
3. Schlünzen, F., Zarivach, R., Harms, J., Bashan, A., Tocilj, A., Albrecht, R., Yonath, A., & Franceschi, F. (2001). "Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria." Nature, 413(6858), 814–821. https://doi.org/10.1038/35101544
4. Wilson, D. N. (2014). "Ribosome-targeting antibiotics and mechanisms of bacterial resistance." Nature Reviews Microbiology, 12(1), 35–48. https://doi.org/10.1038/nrmicro3155